Sanofi announces the superiority of efdoralprin alfa in the treatment of DAAT

At the American Thoracic Society conference in Orlando, Sanofi unveiled promising results from its Phase 2 study of efdoralprin alfa. This experimental treatment demonstrated superior efficacy compared to standard therapy, significantly improving alpha-1 antitrypsin (fAAT) levels in patients with alpha-1 antitrypsin deficiency (ATD). Administered every three weeks, efdoralprin alfa maintained fAAT levels well above the normal range, whereas the current standard only achieves this 41% of the time.

Efdoralprin alfa uses an innovative recombinant approach that could represent a significant advance in the treatment of emphysema caused by DAAT. It offers a less frequent and potentially more durable option than existing plasma-derived therapies.